DK1542961T3 - Trans-4-(3,4-dichlorphenyl)-1,2,3,4-tetrahydro-1-napthalenamin til anvendelse til behandling af cns-forstyrrelser - Google Patents

Trans-4-(3,4-dichlorphenyl)-1,2,3,4-tetrahydro-1-napthalenamin til anvendelse til behandling af cns-forstyrrelser

Info

Publication number
DK1542961T3
DK1542961T3 DK03754641.3T DK03754641T DK1542961T3 DK 1542961 T3 DK1542961 T3 DK 1542961T3 DK 03754641 T DK03754641 T DK 03754641T DK 1542961 T3 DK1542961 T3 DK 1542961T3
Authority
DK
Denmark
Prior art keywords
napthalenamine
dichlorphenyl
tetrahydro
trans
cns
Prior art date
Application number
DK03754641.3T
Other languages
Danish (da)
English (en)
Inventor
Thomas P Jerussi
Qun Kevin Fang
Mark Currie
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DK1542961T3 publication Critical patent/DK1542961T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK03754641.3T 2002-09-16 2003-09-16 Trans-4-(3,4-dichlorphenyl)-1,2,3,4-tetrahydro-1-napthalenamin til anvendelse til behandling af cns-forstyrrelser DK1542961T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41130402P 2002-09-16 2002-09-16
US41130502P 2002-09-16 2002-09-16
PCT/US2003/029110 WO2004024669A1 (en) 2002-09-16 2003-09-16 Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide

Publications (1)

Publication Number Publication Date
DK1542961T3 true DK1542961T3 (da) 2013-11-04

Family

ID=31998027

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03754641.3T DK1542961T3 (da) 2002-09-16 2003-09-16 Trans-4-(3,4-dichlorphenyl)-1,2,3,4-tetrahydro-1-napthalenamin til anvendelse til behandling af cns-forstyrrelser

Country Status (15)

Country Link
US (6) US7087785B2 (enExample)
EP (1) EP1542961B1 (enExample)
JP (1) JP4610336B2 (enExample)
KR (2) KR101067045B1 (enExample)
CN (1) CN101712626B (enExample)
AU (1) AU2003272460B2 (enExample)
BR (1) BRPI0314377B8 (enExample)
CA (1) CA2498152C (enExample)
DK (1) DK1542961T3 (enExample)
ES (1) ES2431519T3 (enExample)
IL (1) IL167319A (enExample)
MX (1) MXPA05002700A (enExample)
NZ (1) NZ538741A (enExample)
PT (1) PT1542961E (enExample)
WO (1) WO2004024669A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0314377B8 (pt) 2002-09-16 2021-05-25 Sepracor Inc composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
EP2343073A3 (en) * 2003-12-11 2011-10-12 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
AU2004312530A1 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
US20060199739A1 (en) * 2005-03-02 2006-09-07 Olav Messerschmidt Limonene-containing herbicide compositions, herbicide concentrate formulations and methods for making and using same
WO2007006003A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2007075173A1 (en) * 2005-12-29 2007-07-05 Utc Power Corporation Circulation of gas-entrained fuel cell coolant
ES2566479T3 (es) * 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción de monoamina con base en tetralona
KR101294014B1 (ko) * 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
EP2816024B8 (en) * 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Chiral amines
AU2013211500B2 (en) * 2006-03-31 2016-08-04 Sepracor Inc Preparation of chiral amides and amines
JP2009538925A (ja) * 2006-05-31 2009-11-12 セプラコール， インク． ｔｒａｎｓ４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドを用いる疼痛性障害の治療
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
BRPI0717171B1 (pt) * 2006-09-25 2023-10-17 Archer Daniels Midland Company Material superabsorvente
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
ZA200904686B (en) * 2007-01-18 2010-09-29 Sepracor Inc Inhibitiors of D-amino acid oxidase
CN101686672A (zh) 2007-05-31 2010-03-31 塞普拉柯公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
CN102573823B (zh) * 2009-05-13 2015-01-07 桑诺维恩药品公司 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
CA2782240A1 (en) * 2009-12-04 2011-06-09 Sunovion Pharmaceuticals Inc. Formulations, salts and polymorphs of transnorsertraline and uses thereof
US8883815B2 (en) 2011-05-19 2014-11-11 Gilrose Pharmaceuticals, Llc Treatment for cerebral palsy impaired speech in children
US20140163070A1 (en) 2012-05-17 2014-06-12 Bruce Roseman Treatment for cerebral palsy impaired speech in children
US9682073B2 (en) 2011-05-19 2017-06-20 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder gait and limb impairments treatment
US10085414B2 (en) 2011-05-19 2018-10-02 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
US9220712B2 (en) 2011-05-19 2015-12-29 Gilrose Pharmaceuticals, Llc Pharmaceutical intervention and method for treating an apraxia of speech in children
WO2012158892A2 (en) 2011-05-19 2012-11-22 Bruce Roseman A method of treating apraxia of speech in children
JP2017515849A (ja) * 2014-05-13 2017-06-15 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Ａｄｈｄを治療するためのダソトラリン用量および治療方法
EP3142999A4 (en) * 2014-05-13 2017-12-27 Sunovion Pharmaceuticals Inc. Methods and compositions of dasotraline for treatment of adhd
WO2016046669A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of depression and neurological diseases
US20200405867A1 (en) * 2018-01-19 2020-12-31 Sunovion Pharmaceuticals Inc. Oral dosage forms
WO2020092496A1 (en) 2018-10-31 2020-05-07 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders
EP3800178A1 (en) 2019-10-01 2021-04-07 Moehs Ibérica, S.L. Preparation of enamide intermediate for the synthesis of dasotraline

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS59497B2 (ja) * 1979-11-01 1984-01-07 フアイザ−・インコ−ポレ−テツド トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5778986A (en) * 1997-08-05 1998-07-14 Davis; Floyd A. Device to remove divots
US6245782B1 (en) * 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
BRPI0314377B8 (pt) * 2002-09-16 2021-05-25 Sepracor Inc composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto

Also Published As

Publication number Publication date
MXPA05002700A (es) 2005-09-08
IL167319A (en) 2013-10-31
AU2003272460A1 (en) 2004-04-30
US20060216799A1 (en) 2006-09-28
PT1542961E (pt) 2013-11-05
US20090292026A1 (en) 2009-11-26
BRPI0314377B1 (pt) 2020-11-24
US7790772B2 (en) 2010-09-07
AU2003272460A2 (en) 2004-04-30
ES2431519T3 (es) 2013-11-26
US20060014982A1 (en) 2006-01-19
US20060128993A1 (en) 2006-06-15
CA2498152A1 (en) 2004-03-25
CN101712626B (zh) 2013-11-20
CA2498152C (en) 2012-01-10
US7423179B2 (en) 2008-09-09
US20040092605A1 (en) 2004-05-13
US20080280993A1 (en) 2008-11-13
AU2003272460B2 (en) 2009-12-17
KR20050084552A (ko) 2005-08-26
US7105699B2 (en) 2006-09-12
EP1542961A1 (en) 2005-06-22
BRPI0314377B8 (pt) 2021-05-25
JP2005539068A (ja) 2005-12-22
KR101165549B1 (ko) 2012-07-19
NZ538741A (en) 2007-01-26
JP4610336B2 (ja) 2011-01-12
US7087785B2 (en) 2006-08-08
US7589237B2 (en) 2009-09-15
KR20110091043A (ko) 2011-08-10
CN101712626A (zh) 2010-05-26
EP1542961B1 (en) 2013-09-11
KR101067045B1 (ko) 2011-09-22
WO2004024669A1 (en) 2004-03-25
BR0314377A (pt) 2005-07-19
HK1143559A1 (en) 2011-01-07

Similar Documents

Publication Publication Date Title
DK1542961T3 (da) Trans-4-(3,4-dichlorphenyl)-1,2,3,4-tetrahydro-1-napthalenamin til anvendelse til behandling af cns-forstyrrelser
NO20041075L (no) Ny 1, 2, 4-triazolforbindelse
ATE452683T1 (de) 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3- methyl-5-oxo-4h-pyrazol-4-yliden hydrazino -2'- hydroxy- 1,1'-biphenyl -3-carbonsaure-bis- (monoethanolamin)
ATE525377T1 (de) Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
DK1504126T3 (da) Fremgangsmåde til regulering af genekspression
DE50206843D1 (de) Koffer, insbesondere werkzeugmaschinenkoffer
DE60310069D1 (de) Netzwerksicherheit
ATE419254T1 (de) 5-ää(2,3-difluorophenyl)methylüthioü-7-ää2- hydroxy-1-(hydroxymethyl)-1-
SE0301827L (sv) Verktyg
DE50308324D1 (de) 2-phenyl-2-substituirte-1, 3-diketone als schädlingsbekämpfungsmittel
NO20041910D0 (no) Fremgangsmate for installasjon av stigeror, samt stigeror
EP1566446A4 (en) BETA-1,4-MANNOBIOSE-CONTAINING COMPOSITION
NO20032767D0 (no) Kjöreverktöy for brönnverktöy
DE50211757D1 (de) Werkzeug
DK1699747T3 (da) Fremgangsmåde til fremstilling af 2,3-cis-substitueret 2-arylpropenaler
DE10358553B8 (de) Zange, insbesondere Ösenzange
ES1054682Y (es) Paso salvacunetas perfeccionado.
DK1497256T3 (da) Substituerede 1,5-diaminopentan-3-ol-forbindelser
ES1053321Y (es) Cajon flamenco perfeccionado.
ATA8492002A (de) Werkzeug
DE50301007D1 (de) Sportschuh, insbesondere skischuh
FR2838073B1 (fr) Pince multi-usages
ATA622002A (de) Werkzeug
ITRM20030163V0 (it) Protezione monouso per lavandini.
ITNA20010034V0 (it) Attrezzo per ginnastica isotonica-isometrica.